DO-BO

How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?

Discover the newest episode of MAP, the Market Access Podcast, your go-to podcast for all things Market Access. In todays episode our host Dr. Stefan Walzer dives deep into early market access in commercialization planning, bridging the gap between innovation and market success. Joined by Catherine Bacon, founder of Fingerpost Consulting, the conversation unpacks the critical steps early-stage healthcare companies must take to ensure patient access, maximize funding, and achieve commercial success.

Explore the importance of early market access in commercialization planning. Learn how to align clinical trials, evidence generation, and payer requirements to ensure patient access and commercial success. Whether you’re aiming for a successful exit or launching your own product, this episode is packed with actionable advice to secure your path to market success by 2030 and beyond.

Tune in to the full episode and explore how Market Access 4.0 is transforming healthcare commercialization!

Related

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]

In this brand new episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, […]

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement. The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as […]